Stocks and Investing
Stocks and Investing
Tue, January 3, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mark Massaro Initiated (SOPH) at Strong Buy and Held Target at $6 on, Jan 3rd, 2023
Mark Massaro of BTIG, Initiated "SOPHiA GENETICS SA" (SOPH) at Strong Buy and Held Target at $6 on, Jan 3rd, 2023.
Mark has made no other calls on SOPH in the last 4 months.
There are 2 other peers that have a rating on SOPH. Out of the 2 peers that are also analyzing SOPH, 1 agrees with Mark's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Phil Winslow of "Credit Suisse" Initiated at Hold and Held Target at $2 on, Wednesday, November 23rd, 2022
This is the rating of the analyst that currently disagrees with Mark
- Tejas Savant of "Morgan Stanley" Maintained at Buy with Decreased Target to $12 on, Wednesday, November 9th, 2022
Contributing Sources